Investment opportunity
The biotech company Oxford Biosensors has been put up for sale following the withdrawal of its existing funders.
The company has developed technology for point-of-care electro-chemical testing for lipids and other analytes, for use in the cholesterol, diabetes and renal function diagnostic testing markets.
Oxford Biosensors’ lead product is a lipid diagnostic panel for monitoring patients’ cardiac risk and the impact of therapy, leading to an improvement in clinical outcomes. The panel enables the testing to be undertaken in the doctor’s office in about five minutes with results comparable to those performed in a clinical laboratory. This product is now being finalised for FDA approval and launch.
In addition, the company has begun work on products for metabolic conditions, diabetes and renal function. Initial feasibility on these pipeline products has already been completed.
Since 2000, the company has raised approximately £18million including equity, grants and corporate partnership revenues. This has enabled the company to drive forward and validate its programmes and establish corporate partnerships.
The company operates from a fully-equipped research and development facility at Yarnton, Oxford.
Expressions of interest are urgently being sought from parties either wishing to either acquire the company or purchase the business and assets.
For further information, contact Roland Cramp at Edward Symmons: [email protected]
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
